---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-063352"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:56:09.325248+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Renalytix Q1 FY2024 revenue drops 50% YoY to $0.5M; net loss $10.2M; cost cuts underway

## Summary
- Revenue $0.5M, down 50% from $1.0M in Q1 FY2023; net loss $10.2M vs $12.0M.
- Cost cutting to reduce payroll >35% and total SG&A >30% YoY; cash $13.9M.
- Testing volumes 1,297 (56% billable); CMS recommended $950/test for kidneyintelX.dkd, decision Dec 2023.
- Howard Doran appointed chief business officer; financing discussions for runway through early 2026.
- Expanded commercial payor coverage: BlueCross BlueShield Texas (7M members), Parkland, PNOA.

## SEC filing metadata
- accession: 0000950170-23-063352
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017023063352/0000950170-23-063352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017023063352/rnlx-20231114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-063352
- JSON: https://secwatch.observer/filing/0000950170-23-063352.json
- Plain text: https://secwatch.observer/filing/0000950170-23-063352.txt

## Key facts
- Earnings Releases
  Renalytix plc reported first quarter ended September 30, 2023 results: revenue $0.5 million, net income Net loss was $10.2 million.
  - Period: first quarter ended September 30, 2023
  - Revenue: $0.5 million
  - Net income: Net loss was $10.2 million
  - Result: reported results
  source text: During the three months ended September 30, 2023, the Company recognized $0.5 million of revenue, compared to $1.0 million for the three months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811115/000095017023063352/0000950170-23-063352-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.